Results 81 to 90 of about 19,421 (203)

Abnormal coagulation profile in people living with HIV-AIDS on combined Antiretroviral Therapy: findings from a case-control study in the Ho municipality, Ghana

open access: yesThe Pan African Medical Journal, 2018
INTRODUCTION: Although combined Anti-Retroviral Therapy (cART) has improved the quality of life and survival in people living with HIV-AIDS (PLWHA), there have been reports of increased non-AIDS related co-morbidities such as coagulopathies.
Richard Kobina Dadzie Ephraim   +6 more
doaj   +1 more source

2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine

open access: yesMolecules, 2013
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. Currently, NVP is the most widely used anti-HIV drug in developing countries, both in combination therapy and to prevent mother-to-child transmission of HIV.
M. Matilde Marques   +4 more
doaj   +1 more source

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

open access: yes, 2013
Includes bibliographical references.Sub-Saharan Africa is overwhelmed by dual epidemics of human immunodeficiency virus (HIV) and tuberculosis (TB) infection.
Cohen, Karen
core  

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity

open access: yes, 1994
The potential use of an alternating treatment strategy with nevirapine and zidovudine in prolonging the antiretroviral effects of nevirapine was evaluated.
Imrie, A.   +9 more
core   +1 more source

Nevirapine induced toxic epidermal necrolysis and non-Hodgkin lymphoma in a Human Immunodeficiency Virus positive patient

open access: yesIndian Dermatology Online Journal, 2014
Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) is one of the important components of highly active antiretroviral therapy. It is sometimes associated with life-threatening adverse reactions.
Leelavathy Budamakuntla   +4 more
doaj   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

open access: yesHIV Medicine, Volume 27, Issue 4, Page 572-584, April 2026.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini   +24 more
wiley   +1 more source

FORMULATION AND EVALUATION OF NEVIRAPINE MUCOADHESIVE MICROSPHERES [PDF]

open access: yes, 2015
Objective: The objective of the present research was to formulate and evaluate HPMC K4M, HPMC K100, and Carbopol 940 Mucoadhesive microspheres in combination with sodium alginate for controlling release of Nevirapine.
Ararath, Dasari, Velmurugan, Sellappan
core  

Chemical and Toxicological Analysis of Antiretroviral Drugs

open access: yesРазработка и регистрация лекарственных средств, 2019
Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov   +7 more
doaj   +1 more source

Exposure of Allium cepa root cells to zidovudine or nevirapine induces cytogenotoxic changes.

open access: yesPLoS ONE, 2014
Antiretroviral drugs have proved useful in the clinical management of HIV-infected persons, though there are concerns about the effects of exposure to these DNA-reactive drugs.
Chika K Onwuamah   +5 more
doaj   +1 more source

Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure

open access: yes, 2010
Background: Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus.
Y. Zheng   +58 more
core   +1 more source

Home - About - Disclaimer - Privacy